SIAH2 and cancer: m6A‐modified Siah2 transcript is degraded by YTHDF2; this results in the upregulation of PD‐L1 in the cancer cell surface leading to an altered response to pembrolizumab.[91] WTAP‐mediated m6A modification also contributes to increased anti‐PD‐1 therapy resistance in HCC cells.